Roanoke Asset Management Corp NY Sells 2,500 Shares of Option Care Health, Inc. (NASDAQ:OPCH)

Roanoke Asset Management Corp NY decreased its position in Option Care Health, Inc. (NASDAQ:OPCH) by 2.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 94,740 shares of the company’s stock after selling 2,500 shares during the period. Roanoke Asset Management Corp NY owned 0.06% of Option Care Health worth $2,198,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Creative Planning lifted its stake in Option Care Health by 116.7% in the third quarter. Creative Planning now owns 38,149 shares of the company’s stock worth $1,194,000 after acquiring an additional 20,546 shares during the period. Raymond James & Associates lifted its position in shares of Option Care Health by 6.3% in the 3rd quarter. Raymond James & Associates now owns 85,279 shares of the company’s stock worth $2,669,000 after purchasing an additional 5,049 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Option Care Health by 3,029.7% during the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company’s stock valued at $91,000 after purchasing an additional 2,757 shares in the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Option Care Health during the third quarter valued at approximately $206,000. Finally, State of Alaska Department of Revenue increased its holdings in Option Care Health by 3.8% during the third quarter. State of Alaska Department of Revenue now owns 19,871 shares of the company’s stock valued at $621,000 after buying an additional 735 shares during the period. Institutional investors own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

OPCH has been the topic of several recent research reports. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and dropped their target price for the company from $38.00 to $27.00 in a research report on Monday, November 4th. Truist Financial cut their target price on Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Barrington Research increased their price target on shares of Option Care Health from $33.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday. Bank of America upgraded shares of Option Care Health from a “neutral” rating to a “buy” rating and raised their price target for the company from $26.00 to $33.00 in a report on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a research note on Friday, January 10th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.88.

Option Care Health Stock Performance

OPCH opened at $33.50 on Friday. The company has a market cap of $5.70 billion, a P/E ratio of 28.15, a price-to-earnings-growth ratio of 2.30 and a beta of 1.35. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The firm’s 50-day moving average price is $28.70 and its 200-day moving average price is $28.09. Option Care Health, Inc. has a 52-week low of $21.39 and a 52-week high of $34.17.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.